HUE052285T2 - Makromolekulák - Google Patents

Makromolekulák

Info

Publication number
HUE052285T2
HUE052285T2 HUE12797060A HUE12797060A HUE052285T2 HU E052285 T2 HUE052285 T2 HU E052285T2 HU E12797060 A HUE12797060 A HU E12797060A HU E12797060 A HUE12797060 A HU E12797060A HU E052285 T2 HUE052285 T2 HU E052285T2
Authority
HU
Hungary
Prior art keywords
macromolecules
Prior art date
Application number
HUE12797060A
Other languages
English (en)
Hungarian (hu)
Inventor
David Owen
Brian Devlin Kelly
Peter Karellas
Original Assignee
Starpharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Starpharma Pty Ltd filed Critical Starpharma Pty Ltd
Publication of HUE052285T2 publication Critical patent/HUE052285T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02Polyamines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10Alpha-amino-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40Polyamides containing oxygen in the form of ether groups
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002Dendritic macromolecules
    • C08G83/003Dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Bipolar Transistors (AREA)
HUE12797060A 2011-06-06 2012-06-06 Makromolekulák HUE052285T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161493886P 2011-06-06 2011-06-06

Publications (1)

Publication Number Publication Date
HUE052285T2 true HUE052285T2 (hu) 2021-04-28

Family

ID=47295262

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12797060A HUE052285T2 (hu) 2011-06-06 2012-06-06 Makromolekulák

Country Status (18)

Country Link
US (2) US9744246B2 (2)
EP (1) EP2729179B1 (2)
JP (1) JP6158177B2 (2)
KR (1) KR101941318B1 (2)
CN (2) CN110124051B (2)
AU (1) AU2012267200B2 (2)
BR (1) BR112013031556B1 (2)
CA (1) CA2837979C (2)
DK (1) DK2729179T3 (2)
ES (1) ES2834992T3 (2)
HR (1) HRP20201998T1 (2)
HU (1) HUE052285T2 (2)
IN (1) IN2014DN00101A (2)
LT (1) LT2729179T (2)
PL (1) PL2729179T3 (2)
PT (1) PT2729179T (2)
SI (1) SI2729179T1 (2)
WO (1) WO2012167309A1 (2)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180326081A1 (en) * 2011-06-06 2018-11-15 Starpharma Pty Ltd Macromolecules
EP2996726A1 (fr) * 2013-05-16 2016-03-23 Université de Strasbourg Composés dendritiques comprenant un agent chélatant, fluorochrome ou agent de reconnaissance, compositions les comprenant et leurs utilisations
WO2015035446A1 (en) * 2013-09-10 2015-03-19 Starpharma Pty Ltd Macromolecules of dendrimer-platinum conjugates
US10730999B2 (en) 2014-06-06 2020-08-04 Starpharma Pty Ltd Dendrimer-drug conjugates
JP6772199B2 (ja) 2015-08-11 2020-10-21 コヒレント バイオファーマ 多リガンド−薬物複合体及びその使用
CN106554329B (zh) * 2015-09-26 2019-07-05 南京友怡医药科技有限公司 水溶性紫杉醇抗癌药物化合物及其制备方法和应用
CN106554330B (zh) * 2015-09-26 2019-07-05 南京友怡医药科技有限公司 水溶性多西他赛抗癌药物化合物及其制备方法和应用
WO2017068051A1 (en) * 2015-10-21 2017-04-27 Lek Pharmaceuticals D.D. Peg-based dendron and process for producing the same
WO2017135893A1 (en) * 2016-02-05 2017-08-10 Nipsea Technologies Pte Ltd Aqueous dendritic amine coatings
US20190142953A1 (en) * 2016-05-10 2019-05-16 Massachusetts Institute Of Technology Dendrimer-Drug Conjugates, Hydrogel Compositions, and Methods
TWI773730B (zh) * 2017-02-22 2022-08-11 瑞典商阿斯特捷利康公司 治療性樹枝狀聚合物
JP7249591B2 (ja) * 2018-03-29 2023-03-31 日油株式会社 分解性ポリエチレングリコール結合体
US12071517B2 (en) * 2018-07-19 2024-08-27 Starpharma Pty Ltd. Therapeutic dendrimer
WO2020014750A1 (en) * 2018-07-19 2020-01-23 Starpharma Pty Ltd Therapeutic dendrimer
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法
TWI856967B (zh) 2018-08-17 2024-10-01 瑞典商阿斯特捷利康公司 樹枝狀體配製物
KR102948775B1 (ko) * 2018-11-20 2026-04-03 스타파마 피티와이 리미티드 치료 덴드리머
JP7541978B2 (ja) * 2018-11-29 2024-08-29 スターファーマ ピーティーワイ エルティーディー 治療および画像化のためのデンドリマー
BR112022003628A2 (pt) * 2019-08-28 2022-05-24 Starpharma Pty Ltd Conjugados de dendrímero direcionado
EP4034169B1 (en) * 2019-09-26 2026-02-11 Starpharma Pty Limited Therapeutic dendrimer
WO2021213492A1 (zh) * 2020-04-24 2021-10-28 上海森辉医药有限公司 一类载药的大分子及其制备方法
KR20230065935A (ko) * 2020-06-03 2023-05-12 스타파마 피티와이 리미티드 치료적 접합체
BR112023002855A2 (pt) 2020-08-25 2023-04-25 Shanghai Senhui Medicine Co Ltd Macromolécula carregada com fármaco e método de preparação para a mesma
EP4203968A4 (en) * 2020-08-31 2025-07-30 Starpharma Pty Ltd DENDRIMER-DRUG CONJUGATE
EP3973952B1 (en) * 2020-09-24 2024-02-14 Ocular Therapeutix, Inc. Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine
EP4216929A1 (en) * 2020-09-24 2023-08-02 Ocular Therapeutix, Inc. Sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent
CN117164357B (zh) * 2023-01-03 2024-07-19 广东捷成科创电子股份有限公司 一种五元系大功率型压电陶瓷材料及其制备方法
TW202448514A (zh) * 2023-05-08 2024-12-16 大陸商上海森輝醫藥有限公司 抗真菌藥的載藥大分子及其製備方法
CN118063414B (zh) * 2024-02-29 2026-04-28 常州大学 一种半胱氨酸-多西他赛偶联物及其制备方法和应用
WO2026046228A1 (zh) * 2024-08-27 2026-03-05 苏州拓界医药有限公司 树枝状聚合物偶联物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
CN101102787A (zh) * 2004-08-09 2008-01-09 艾丽奥斯生物制药有限公司 合成的超糖基化、抗蛋白酶的多肽变体、口服制剂及其使用方法
CN101002945B (zh) * 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
JP5989294B2 (ja) * 2006-01-20 2016-09-07 スターファーマ・プロプライエタリー・リミテッドStarpharma Pty Ltd 修飾高分子
US8420067B2 (en) * 2006-08-11 2013-04-16 Starpharma Pty Ltd Targeted polylysine dendrimer therapeutic agent
ES2672526T3 (es) 2008-06-26 2018-06-14 Prolynx Llc Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas
WO2011072290A2 (en) * 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Targeted dendrimer-drug conjugates
ES2584381T3 (es) * 2010-05-05 2016-09-27 Prolynx Llc Liberación controlada de compuestos activos desde conjugados macromoleculares
US8703907B2 (en) 2010-05-05 2014-04-22 Prolynx Llc Controlled drug release from dendrimers
EP2566334B1 (en) 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports

Also Published As

Publication number Publication date
KR20140041678A (ko) 2014-04-04
PT2729179T (pt) 2020-11-25
JP2014520105A (ja) 2014-08-21
LT2729179T (lt) 2020-12-28
US20140171375A1 (en) 2014-06-19
IN2014DN00101A (2) 2015-05-15
JP6158177B2 (ja) 2017-07-05
CN110124051A (zh) 2019-08-16
EP2729179A4 (en) 2015-01-28
SI2729179T1 (sl) 2021-01-29
US9744246B2 (en) 2017-08-29
US20170354739A1 (en) 2017-12-14
PL2729179T3 (pl) 2021-07-19
AU2012267200B2 (en) 2016-02-25
KR101941318B1 (ko) 2019-01-22
AU2012267200A1 (en) 2013-05-09
CA2837979A1 (en) 2012-12-13
HRP20201998T1 (hr) 2021-02-05
CN103796684B (zh) 2019-06-25
EP2729179B1 (en) 2020-09-23
CN110124051B (zh) 2022-10-21
HK1198356A1 (en) 2015-04-10
US10265409B2 (en) 2019-04-23
EP2729179A1 (en) 2014-05-14
CA2837979C (en) 2021-03-30
BR112013031556A2 (2) 2017-08-29
BR112013031556B1 (pt) 2022-03-29
ES2834992T3 (es) 2021-06-21
CN103796684A (zh) 2014-05-14
DK2729179T3 (da) 2020-12-21
WO2012167309A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
LT2729179T (lt) Makromolekulės
DK3505720T3 (en) Cementering under styret tryk
DK3798230T3 (en) Terapeutiske antistoffer
DK2691417T4 (en) Antistof fc-varianter
EP2755962A4 (en) AZAINDAZOLES
EP2754063A4 (en) EXTENSIBILITY OF THE SMB2 PROTOCOL
EP2723631A4 (en) QUADFOILER
EP2776444A4 (en) dihydropteridinones
AP2014007621A0 (en) 2-Thiopyrimidinones
PL2699681T3 (pl) Hipoalergeny
DK2770906T3 (en) Applanationstonometer
GB201101727D0 (en) Obuoy
GB201100001D0 (en) TidySqueeze2
AU4540P (en) BUNNAN Baloskion tetraphyllum
AU5171P (en) Sunparamiho Mandevilla xamabilis
AU5031P (en) BESYS Beschorneria yuccoides
AU5026P (en) Goldstrike Agapanthus inapertus
GB201102066D0 (en) Scottscraper
GB201101931D0 (en) Kerbknight
GB201101143D0 (en) Post-reference
GB201100359D0 (en) Fedorak-a-lope
GB201100308D0 (en) CrossPic
GB201100168D0 (en) SecuriPad
GB201100055D0 (en) Evac-sac
GB201102679D0 (en) Ex-connector